Levicept Ltd is a UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. LEVI-04 is currently in a phase II study in patients with osteoarthritis of the knee.
| Website | http://www.levicept.com |
| Revenue | $5 million |
| Funding | $16 million |
| Employees | 11 (4 on RocketReach) |
| Founded | 2012 |
| Phone | +1 447-590-8153 |
| Technologies |
JavaScript
,
HTML
,
Nginx
+5 more
(view full list)
|
| Industry | Biotechnology, Biotechnology Research, Biopharma, Pharmaceuticals, Healthcare, Health Care, Science and Engineering, Medical Device |
| Keywords | Biotechnology, Pharmaceutical, Biological Therapy, Drug Development, Pain Treatment, Clinical Trials, Novel Therapy, Immunotherapy, Chronic Pain, Phase 2 Trials, Osteoarthritis Treatment, Knee Pain |
| Competitors | Johnson & Johnson, Roche, Novartis, Merck & Co., Inc., Pfizer, Bristol Myers Squibb, Genentech, Amgen, Boehringer Ingelheim, Lilly India +41 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular LEVICEPT LTD employee's phone or email?
The LEVICEPT LTD annual revenue was $5 million in 2026.
Eliot Forster is the CEO of LEVICEPT LTD.
4 people are employed at LEVICEPT LTD.
The NAICS codes for LEVICEPT LTD are [325, 32, 3254, 32541].
The SIC codes for LEVICEPT LTD are [283, 28].